Companies similar to GENOMEFRONTIER
Sign up to Download

1-30 of 52,458 results

  • immcantation.readthedocs.io
  • 1
Advances in high-throughput sequencing technologies now allow for large-scale characterization of B cell receptor (BCR) and T cell receptor (TCR) repertoires. The high germline and somatic diversity of the adaptive immune receptor repertoire (AIRR)..
Relevance: 33.85258
  • www.for2799.de
  • 9
  • 2
  • 2
Current research on γδ T cells and their γδ TCR focusses on the identification of potential ligands for the γδ TCR, the role of γδ T cells in the control of infectious diseases, and the potential of γδ T cells for novel therapies against tumors...
Relevance: 32.281914
  • nusilols.weebly.com
A Monoclonal antibody with T-cell receptor-like specificity that targets Epstein-Barr infected human tumour cells..
Relevance: 32.00509
  • genomefrontier.com
  • 1
  • 1
  • 5
Using the Quantum Engine™, GenomeFrontier is developing multiple cell modified gene therapy products, including chimeric antigen receptor T (CAR-T) and T cell receptor T (TCR-T) therapies. These are live, cell-based "drugs" composed of immune cells..
Relevance: 32.00359
  • allogene.com
  • 4
  • 2
  • 27
Allogene is developing allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapy to find the next immunologic breakthrough in cancer. That's how we're leading today, creating tomorrow... Our mission is to create and lead the next revolution..
Relevance: 31.078337
  • www.famicordtx.com
  • 1
  • 3
  • 1
FamiCordTx is a company established to implement cell engineering therapies. Our main goal is to implement therapy based on CAR-T (chimeric antigen receptor) technology, i.e. genetically modified T-cells used for blood neoplasm treatment.wi...
Relevance: 30.43991
  • tdrdna.com
  • 1
Co-led design of chimeric antigen receptor T cell (UltraCAR-T®) therapy product development strategy, including invention, acquisition, and optimization of systems required for scalable decentralization of autologous GM-T Cell production (2012-19).....
Relevance: 30.158403
  • www.t-knife.com
  • 3
  • 3
  • 12
T-knife Therapeutics is a biopharmaceutical company dedicated to developing novel therapeutics to fight cancer... We are focused on T cell receptor engineered T cell therapies, TCR-Ts, a promising modality that holds the potential to generate..
Relevance: 29.401955
  • www.biontech.com
  • 3
  • 3
  • 13
We aim to bring novel oncology and infectious disease therapies to the market. BioNTech is also exploring how to apply its technology to advancements in treating allergies, inflammatory diseases, and regenerative medicine... BioNTech is a fully..
Relevance: 29.102436
  • www.mytcelltherapies.com
  • 1
Find out how the innovative Chimeric Antigen Receptor (CAR) T cell therapy can help turn a potential cure into your reality... This website is created in the English language. Novartis has not certified or validated the accuracy of any translation..
Relevance: 29.029207
  • imgsb.org
  • 2
  • 1
  • 12
Understanding the role of Nuclear receptor co-repressors, Zinc finger TFs, Nuclear receptor co-regulators in Cd8a+ dendritic cells... Understanding the underlying mechanism of adaptive immune response using Next Generation Sequencing technology and..
Relevance: 28.925362
  • www.repertoireanalysis.com
Using advanced patten matching techniques, we developed a method to reliably identify complementarity-determining regions (CDR1, CDR2 and CDR3) in both immunoglobulin (Ig) and T cell receptor (TR) sequences from multiple species using Kabat or IMGT..
Relevance: 27.953638
  • ndd-europe.com
Advances in the Knowledge of the Molecular Biology of Glioblastoma and Its Impact in Patient Diagnosis, Stratification, and Treatment... T cell receptor repertoire as a prognosis marker for heat shock protein peptide complex-96 vaccine trial against..
Relevance: 27.943443
  • celyad.com
  • 2
  • 2
  • 14
Celyad Oncology is a cutting-edge biotechnology company dedicated to pioneering the discovery and advancement of revolutionary technologies for chimeric antigen receptor (CAR) T-cells. Its primary objective is to unlock the potential of its..
Relevance: 27.840237
  • www.aurora-biopharma.com
  • 1
  • 2
  • 13
Aurora Biopharma is founded on a single mission to revolutionize the treatment of cancer, by using the human body's immune system. Aurora is developing state-of-the-art cancer immunotherapy, a form of adoptive cell transfer called Chimeric Antigen..
Relevance: 27.29211
  • www.cabalettabio.com
  • 5
  • 2
  • 22
Cabaletta Bio is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Our proprietary Cabaletta Approach to B cell Ablation (CABA®) platform is designed to provide..
Relevance: 26.196228
  • www.cellchat.org
CellChat Explorer contains two major components: (a) Ligand-Receptor Interaction Explorer that allows easy exploration of our ligand-receptor interaction database, and (b) Cell- Cell Communication Atlas Explorer that allows easy exploration of the..
Relevance: 26.013172
  • biocircuits.github.io
13. Promiscuous receptor-ligand interactions increase the bandwidth and specificity of cell-cell communication systems..
Relevance: 25.923983
  • abatatx.com
  • 3
  • 18
Abata was launched in 2021 by Third Rock Ventures with a $95 million Series A financing and brings together industry experts and deeply engaged pioneers in regulatory T cell (Treg) biology, T cell receptor (TCR) and antigen discovery, disease..
Relevance: 25.593018
  • www.glycostem.com
  • 2
  • 1
  • 15
Glycostem is developing a pipeline of cellular immunotherapy therapies, which has the potential to redefine standards of care across various type of cancer. Besides of oNKord® as our lead investigational product, we are developing viveNK TM, Chimeric..
Relevance: 25.391193
  • docs.immunedb.com
ImmuneDB is a database-backed system to analyze and store large amounts (terabytes) of high-throughput B-cell receptor (BCR) and T-cell receptor (TCR) data. Although it can be used as a stand-alone package for comprehensive repertoire profiling,..
Relevance: 25.245647
  • immunecyte.com
  • 1
  • 2
ImmuneCyte is a clinical stage cell therapy company focused on delivering critical impacts on cancer, vascular, orthopedic, and aging-related diseases... ImmuneCyte Inc. is a global, clinical-stage biopharmaceutical company engaged in the research..
Relevance: 24.811184
  • acmbcb.org
a 50-65 kDa Fcg receptor IIIa FcgRIII) a 55 kDa cell surface receptor. It is a member of the lg superfamily ARHGEF11 Arry-380 a subset of T cells as well as in signal transduction and NK cell activation. The CD16 blocks the binding of soluble immune..
Relevance: 24.725592
  • zji90.github.io
  • 1
My primary research interest is developing novel statistical and computational methods for integrating and analyzing big and complex genomic data, especially data from single-cell sequencing and spatial transcriptomics. Some examples include the..
Relevance: 24.724161
  • www.gencytetherapeutics.com
Gencyte Therapeutics is focused on the development of the next-generation of Chimeric Antigen Receptor T-cell (CAR-T) immunotherapy for precision cancer treatment... We believe that the time is right for a new approach. We believe that there is an..
Relevance: 24.418127
  • t2evolve.com
  • 4
  • 1
  • 2
T2EVOLVE is a new breakthrough alliance of academic and industry leaders in cancer immunotherapy under the European Union's Innovative Medicines Initiative (IMI). The key objective of T2EVOLVE is to accelerate development and increase awareness and..
Relevance: 23.7304
  • www.medigene.com
  • 6
  • 6
  • 8
Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. With its scientific expertise, Medigene is working on the development of innovative..
Relevance: 23.628128
  • signablok.com
  • 1
  • 1
SignaBlok, Inc. is a biopharmaceutical company founded in 2009 to develop novel mechanism-based targeted therapeutics and delivery nanosystems through the use of our revolutionary science and technologies... SignaBlok's elegant approach for..
Relevance: 23.19949
  • tpis.upmc.com
  • 3
  • 2
DISCLAIMER: Transplant Pathology Internet Services makes no warranties that the information contained herein is in every respect accurate or complete, and is not responsible for any errors or omissions or for the results obtained from the use of..
Relevance: 22.713509
  • ireceptor.irmacs.sfu.ca
  • 1
  • 11
iReceptor is a project located at the IRMACS Centre at Simon Fraser University. It is funded by the CANARIE Network Enabled Platforms Program, the Canada Foundation for Innovation (CFI), the British Columbia Knowledge Development Fund (BCKDF), the..
Relevance: 22.51645